OPCH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Option Care Health Inc (OPCH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock has positive insider buying trends, favorable analyst ratings with increased price targets, and a strong position in the healthcare services sector. While technical indicators are neutral, the company's financial performance shows revenue growth, and options data suggests bullish sentiment. Given the investor's profile and the absence of significant negative catalysts, OPCH presents a solid long-term investment opportunity.
The MACD histogram is -0.191, below 0, and negatively contracting, indicating a neutral to slightly bearish trend. RSI is at 54.801, in the neutral zone, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. Key support is at 33.237, and resistance is at 34.811. The stock is trading near its pivot point of 34.024, indicating a balanced price action.
Insider buying has surged by 887.63% over the last month, indicating confidence from company insiders.
Analysts have raised price targets significantly, with targets ranging from $35 to $42, reflecting optimism about the company's growth prospects.
The company is well-positioned in the healthcare services sector, with a strong focus on infusion services and home-based care, which are expected to grow.
Revenue increased by 12.24% YoY in Q3 2025, showcasing solid growth.
Net income dropped by -3.79% YoY in Q3 2025, and gross margin decreased by -5.55%, which could indicate some cost pressures.
No recent news or congress trading data to provide additional sentiment or momentum.
Technical indicators are neutral, with no strong bullish signals.
In Q3 2025, revenue increased by 12.24% YoY to $1.435 billion, indicating strong top-line growth. However, net income dropped by -3.79% YoY to $51.82 million, and gross margin declined by -5.55% to 17.88%. EPS increased by 3.23% YoY to 0.32, showing some improvement in earnings per share despite margin pressures.
Analysts are optimistic about OPCH, with multiple firms raising price targets recently. TD Cowen raised its target to $37, Barrington to $42, Stephens to $40, Deutsche Bank to $36, and BofA to $35. Ratings range from Hold to Outperform, with analysts citing the company's strong position in the healthcare sector and potential for upside in FY26 guidance.
